Author's Reply to Srinivas: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection".
Galapagos SASU, 102 Avenue Gaston Roussel, Romainville, France. florence.namour@glpg.com.
Florence
F
Namour
D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D008297:Male; D011725:Pyridines / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D014230:Triazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics*
D018501:Antirheumatic Agents; D011725:Pyridines; D014230:Triazoles